ASCO26. Selpercatinib reduce semnificativ riscul de recidivă în cancerul pulmonar non-microcelular, cu fuziuni RET asociate Raportul de gardă 10:52
#ASCO26. Asandeutertinib depășește eficacitatea osimertinibului în controlul metastazelor cerebrale la pacienții cu NSCLC și mutații EGFR Raportul de gardă 08:44 Mon, 08 Jun
ASCO26 Podcast: an analyst rundown of the best readouts and key trends Pharmaceutical Technology 11:11 Fri, 05 Jun
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess Pharmaceutical Technology 09:50 Fri, 05 Jun
#ASCO26. Agoniștii receptorului GLP-1 ar putea reduce riscul de metastazare cu până la 50% în anumite tipuri de cancer asociate obezității Raportul de gardă 17:30 Wed, 03 Jun
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC Pharmaceutical Technology 09:09 Wed, 03 Jun
ASCO26: In vivo oncology approaches continue to show promise Pharmaceutical Technology 17:13 Tue, 02 Jun
ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC Pharmaceutical Technology 15:32 Tue, 02 Jun
ASCO26: Abbott demonstrates MRD test benefit in TNBC recurrence Verdict Medical Devices 11:36 Tue, 02 Jun
ASCO26: Gastrointestinal cancers enter the limelight amid key readout surge Clinical Trials Arena 09:46 Tue, 02 Jun
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer Pharmaceutical Technology 21:01 Mon, 01 Jun
ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease Pharmaceutical Technology 21:01 Mon, 01 Jun
ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise Clinical Trials Arena 18:08 Mon, 01 Jun
ASCO26: Data highlights test benefit in breast cancer treatment planning and earlier detection Verdict Medical Devices 11:59 Mon, 01 Jun
ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial Clinical Trials Arena 16:38 Fri, 29 May
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting BioPharma Dive 17:42 Fri, 22 May
